PBE ETF
Invesco Biotechnology and Genome ETF
PBE ETF Overview
PBE ETF (Invesco Biotechnology and Genome ETF) is managed by Invesco (US) with $379.4M in net assets. PBE expense ratio is 0.58%, holding 33 positions across sectors including Health Care, Financials. Inception date: 2005-06-23.
PBE performance shows a YTD return of 9.82%. The 1-year return is 39.59% and the 5-year return is 3.94%. PBE dividend yield stands at 1.70%, paid quarterly.
PBE top holdings include Nvaesrtex Pharmaceuticals Inc (5.2%), Biogen Inc. Com (5.1%), Amgen Inc. (4.9%), Royalty Pharma Plc Class A Ordinary Share (4.8%), Regeneron Pharmaceuticals, Inc. (4.5%). Go to all PBE holdings, PBE sectors, or PBE dividends.
PBE can be compared against other funds. Use PBE overlap to find shared positions, or PBE vs another fund for a side-by-side view. PBE alternatives are available via the screener, along with tax-loss harvesting opportunities.